Alzheimer's Research: Separating Demonstrated Progress From Hope
Two approved antibodies slow decline modestly in early disease. Blood tests can detect the pathology. Neither is a cure, and the question of what the disease fundamentally is remains open.
The Daily Edition Future Desk2 min read
Illustrative. This article is demonstration content written to show The Daily Edition. It does not report actual events. Historical and scientific facts are attributed to real sources in the Deep Dive.
Quick Read · about 30 seconds
- What happened
- Lecanemab and donanemab, antibodies that clear amyloid plaques, received full U.S. approval in 2023 and 2024 after trials showing they slowed cognitive decline by roughly a quarter to a third over eighteen months in early disease. Blood tests for amyloid and tau pathology have reached clinical use.
- Why it matters
- These are the first treatments shown to alter the disease's course rather than its symptoms. Their modest size, side effects and cost make them a beginning rather than an answer, and they test the central hypothesis of the field.
- What remains uncertain
- Whether the measured slowing is noticeable to patients and families, how long benefit persists, who should be treated and when, and whether targets beyond amyloid will prove more important.
For thirty years the amyloid hypothesis organized Alzheimer's research, and for most of those years it failed to produce a treatment. That changed between 2021 and 2024, with results that were real, modest and contested. The Future Desk framework separates what has been shown from what is hoped.
What is demonstrated
Two antibodies that remove amyloid plaques from the brain, lecanemab and donanemab, slowed decline on cognitive and functional scales by roughly 25 to 35 percent relative to placebo over about eighteen months in people with early symptomatic disease. The effect was statistically robust in both trials. Both drugs cause brain swelling or small bleeds in a significant minority of patients, usually without symptoms, occasionally seriously. Blood tests measuring amyloid and tau markers now identify the pathology with accuracy approaching that of spinal fluid tests.
What researchers are attempting
Trials are testing anti-amyloid treatment before symptoms appear, in people identified by biomarkers. Antibodies against tau, the protein that forms tangles, are in trials. So are drugs targeting inflammation, metabolism and vascular contributions. Combination approaches are planned.
What experts predict
Future Desk assessment
- Demonstrated today
- Two anti-amyloid antibodies slow decline by roughly a quarter to a third over 18 months in early disease; blood biomarkers detect pathology accurately.
- What researchers are attempting
- Treatment before symptoms; anti-tau and anti-inflammatory therapies; combinations.
- What experts predict
- Incremental improvements and earlier treatment within a decade; no cure in that time, per most researchers.
- What remains speculative
- Prevention in asymptomatic people; reversal of decline; a single cause.
- What would change this assessment
- A positive prevention trial; an effective tau therapy; or long-term data showing trial benefits fade.
The Living Story
Advances in Alzheimer's Research
Two antibody drugs that clear amyloid plaques are approved in the United States and modestly slow decline in early disease. Debate continues over how meaningful that benefit is, who should receive treatment, and whether other biological targets will prove more important.
6 milestones · 2 updates · 1 articles
Open the story pageAsk the Newspaper
Put a question to the research desk. Answers draw only on this article’s verified material and its continuing story, and every statement is cited. No language model is configured, so answers are the most relevant verified passages rather than generated prose.
Related reading
The Promise and Limitations of Personalized Medicine
Sequencing a genome costs less than a night in a hospital. Turning that information into better treatment has proved far harder than the price curve suggested.
2 min read